Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial

Diabetologia

Volumn 59, Issue 11, 2016, Pages 2298-2307

  Gæde, Peter ^a,b   Oellgaard, Jens ^a,b,c   Carstensen, Bendix ^c   Rossing, Peter ^c,d,e   Lund Andersen, Henrik ^c,e,f   Parving, Hans Henrik ^e,g   Pedersen, Oluf ^h  

^a SLAGELSE HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c STENO DIABETES CENTER   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Capital Region Eye Clinic   (Denmark)

^g Rigshospitalet   (Denmark)

^h Capital Region   (Denmark)

Author keywords

Albuminuria; Cardiovascular disease; Diabetes complications; Diabetes mellitus, type 2; Diabetic nephropathy; Diabetic neuropathy; Diabetic retinopathy; Follow up studies; Humans

Indexed keywords

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MICROALBUMINURIA; MIDDLE AGED; MORTALITY RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETINOPATHY; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; AGED; ALBUMINURIA; CARDIOVASCULAR DISEASES; CONTROLLED STUDY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; VERY ELDERLY;

ANTIDIABETIC AGENT;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84982124800     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4065-6     Document Type: Article

References (28)

1. Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58:429–442
2. Tancredi M, Rosengren A, Svensson AM et al (2015) Excess mortality among persons with type 2 diabetes. N Engl J Med 373:1720–1732
3. Cannon CP, Blazing MA, Giugliano RP et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:2387–2397
4. LaRosa JC, Deedwania PC, Shepherd J et al (2010) Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). Am J Cardiol 105:283–287
5. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E (2009) Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol 54:2358–2362
6. Ford I, Murray H, Packard CJ et al (2007) Long-term follow-up of the West of Scotland coronary prevention study. N Engl J Med 357:1477–1486
7. Nissen SE (2009) Cardiovascular outcomes in randomized trials: should time to first event for “hard” end points remain the standard approach? J Am Coll Cardiol 54:2363–2365
8. Tikkanen MJ, Szarek M, Fayyad R et al (2009) Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (incremental decrease in end points through aggressive lipid lowering) trial. J Am Coll Cardiol 54:2353–2357
9. Faerch K, Carstensen B, Almdal TP, Jorgensen ME (2014) Improved survival among patients with complicated type 2 diabetes in Denmark: a prospective study (2002–2010). J Clin Endocrinol Metab 99:E642–E646
10. Gregg EW, Li Y, Wang J et al (2014) Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370:1514–1523
11. Gæde P, Vedel P, Parving HH, Pedersen O (1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the steno type 2 randomised study. Lancet 353:617–622
12. Gæde P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393
13. Gæde P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591
14. Ryden L, Grant PJ, Anker SD et al (2013) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087
15. American Diabetes A (2015) (8) Cardiovascular disease and risk management. Diabetes Care 38(Suppl):S49-57
16. Lynge E, Sandegaard JL, Rebolj M (2011) The Danish National Patient Register. Scand J Public Health 39:30–33
17. Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39:22–25
18. Gerstein HC, Miller ME, Genuth S et al (2011) Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364:818–828
19. Zoungas S, Chalmers J, Neal B et al (2014) Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371:1392–1406
20. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
21. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359:1565–1576
22. Shi L, Ye X, Lu M et al (2013) Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes. Diabetes Care 36:3297–3304
23. Zoungas S, de Galan BE, Ninomiya T et al (2009) Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: new results from the ADVANCE trial. Diabetes Care 32:2068–2074
24. Bittner V, Bertolet M, Barraza Felix R et al (2015) Comprehensive cardiovascular risk factor control improves survival: the BARI 2D trial. J Am Coll Cardiol 66:765–773
25. Lachin JM, Orchard TJ, Nathan DM, Group DER (2014) Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 37:39–43
26. Hayward RA, Reaven PD, Wiitala WL et al (2015) Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 372:2197–2206
27. Advance Study Group (2016) Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care 39:701–708
28. Yusuf S, Lonn E, Pais P et al (2016) Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 374:2032–2043